Taysha Gene Therapies (NASDAQ:TSHA) Insider Sukumar Nagendran Sells 200,000 Shares of Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $4.71, for a total transaction of $942,000.00. Following the completion of the sale, the insider owned 1,006,439 shares in the company, valued at approximately $4,740,327.69. The trade was a 16.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Sukumar Nagendran also recently made the following trade(s):

• On Friday, November 28th, Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total value of $523,093.75.
• On Monday, December 1st, Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.51, for a total value of $1,172,811.97.

Taysha Gene Therapies Price Performance

NASDAQ:TSHA opened at $5.04 on Thursday. The business’s 50-day moving average is $4.97 and its 200 day moving average is $3.93. Taysha Gene Therapies, Inc. has a 12 month low of $1.05 and a 12 month high of $6.02. The company has a market capitalization of $1.38 billion, a P/E ratio of -15.27 and a beta of 1.02. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. On average, equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

Institutional investors have recently made changes to their positions in the company. Xponance Inc. increased its holdings in Taysha Gene Therapies by 29.1% during the third quarter. Xponance Inc. now owns 16,575 shares of the company’s stock valued at $54,000 after buying an additional 3,738 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Taysha Gene Therapies by 33.6% in the third quarter. Principal Financial Group Inc. now owns 16,251 shares of the company’s stock worth $53,000 after buying an additional 4,091 shares during the last quarter. ST Germain D J Co. Inc. raised its stake in Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after acquiring an additional 4,333 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Taysha Gene Therapies by 25.8% during the third quarter. Legal & General Group Plc now owns 23,149 shares of the company’s stock worth $76,000 after purchasing an additional 4,754 shares during the period. Finally, Quantum Private Wealth LLC lifted its stake in Taysha Gene Therapies by 0.7% during the 3rd quarter. Quantum Private Wealth LLC now owns 822,076 shares of the company’s stock valued at $2,688,000 after acquiring an additional 6,100 shares during the period. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Chardan Capital reiterated a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Taysha Gene Therapies in a research report on Friday, October 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price objective on shares of Taysha Gene Therapies in a research note on Friday, November 14th. The Goldman Sachs Group set a $11.00 price objective on Taysha Gene Therapies in a research report on Thursday, December 4th. Finally, UBS Group set a $11.00 target price on Taysha Gene Therapies in a report on Thursday, December 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.